People who are prescribed the anti-coagulant apixaban cite six major reasons for failing to adhere to their prescriptions, including cost and potential bleeding.
The investigators discovered that in moderately ill patients full-dose heparin reduced the need for organ support compared to those who received lower-dose heparin.
Findings from an international multicenter trials showed that while a full dose of heparin didn’t statistically significantly lower incidence of the primary composite of death, mechanical ventilation or ICU admission compared with low-dose heparin, therapeutic heparin did reduce the odds of all-cause death by 78 percent.
A new research paper funded in part by the National Heart, Lung and Blood Institute (NHLBI) shows a clear advantage of genetic testing in helping health care providers choose the appropriate anti-platelet drug. Testing helps determine if a patient carries genetic variants in CYP2C19 that cause loss of its function. These variants interfere with the body’s ability to metabolize and activate clopidogrel, an anti-platelet medication.
While COVID-19 infected patients should be treated with standard anticoagulation therapies, such as blood thinning medication, a new study by researchers at the George Washington University shows that anticoagulating patients at higher doses, without traditional medical indications to do so, may be ineffective and even harmful.
September is National Atrial Fibrillation Month, and Stephen L. Winters, MD, director of the Cardiac Rhythm Management Program, Gagnon Cardiovascular Institute, Atlantic Health System’s Morristown Medical Center, wants the public to know some surprising facts about this increasingly common heart condition.
Study is the basis of a new international clinical trial
Research could change standard of care protocols to prevent clotting associated with coronavirus
A new study from the Icahn School of Medicine at Mount Sinai suggests that blood clots, especially in the lungs, may play a role in severe cases of COVID-19.
A new scientific statement from the American Heart Association identifies the risks and benefits of using novel interventional devices compared to anticoagulation alone to treat patients with pulmonary embolism.